Following the Ergothioniene Manufacturing Patent, NNB Files for a New Patent on Novel Applications for Plus LIFESPAN™ EGT that Include Restoring Ageing Conditions Similar to that of Young and Upregulating DNA Repair Pathways 

The leading ingredient-focused biotech company, NNB, has filed for a patent on Ergothioneine and “Ameliorating Mammalian Aging – Including Humans.”

With another milestone achieved in their a-decade-long clinical investigation into L-Ergothioneine, NNB announced a surprising and novel application for their L-Ergothioneine (MitoPrime™).

Most notable is the benefit of restoring conditions of ageing to those similar of the young. Included in the filing are the detailed bio-mechanistic interactions between orally-dosed L-Ergothioneine and the key molecular targets responsible for the human anti-aging benefits.

• The Ergothioneine transporter OCTN1/ETT was discovered in 2005.

• Ergothioneine transporters (ETT/OCTN1) are densely concentrated in the Mitochondria,playing a specific role in protecting mitochondrial components such as DNA.

• Cells lacking ETT are more susceptible to oxidative stress, resulting in increased mitochondrial DNA damage, protein oxidation and lipid peroxidation

• The American diet is lacking in foods containing Ergothioneine

• EGT is a unique cytoprotectant as it is uni-directional, once it enters the cell it does not exit

Ergothioneine is a naturally occurring amino acid found in the highest concentrations in certain mushroom species. Ergothioneine is unique in that it has its own dedicated nutrient transport protein known as ETT (formerly OCTN1). Termed a “Longevity Vitamin” (by renowned research scientist Dr. Bruce Ames) for its antioxidant capability, the NNB filing elevates Ergothioneine’s role to a target-specific nutrigenomic with age mitigating effects. “We are seeking to confirm the results of our pilot studies involving various health benefits, including immune health, longevity, mitochondrial metabolic activity, antioxidant capacity, anti-inflammation, and mitigation of the long term effects of COVID-19.” said Kylin Liao, founder and CEO of NNB.

Results of NNB’s initial four clinical/ex-vivo studies will be made available on the Clinical Trial section of their MitoPrime website: https://mitoprimennb.com/. The remaining studies are looking into Ergothioneine’s benefit as supplement and topical applications.

Dr. Joseph Evans, former principle investigator at Novartis Pharmaceuticals said, “Now that we know the results of key ageing studies, it certainly appears that NNB L-Ergothioneine offers new possibilities for improving health, wellness, and healthy ageing.”

About MitoPrime™

MitoPrime™ is NNB’s patented, highly enhanced form of L-ergothioneine, known in the scientific community as the “longevity vitamin”. With anti-oxidation capabilities stronger than many other well-known products, this unique ingredient is available in multiple formats. 

About NNB

NNB is the leading ingredient-driven biotech company employing over 100 research scientists from more than 10 countries who study, design, and deliver unique ingredients to industry to maximize health, augment performance, expand longevity and enhance appearance. NNB fosters partnerships with companies in the fields of nutraceuticals, food and beverage and skin care.

Contact Us

Customers can learn more ingredients by visiting the website: www.nnbnutrition.com

Any questions, please contact:

• Sales Director: Amanda (amanda@nnbnutrition.com)

• Product Manager: Clara (clarabao@nnbnutrition.com) 

Media Contact
Company Name: Nanjing Nutrabuilding Bio-tech Co., LTD. (NNB Nutrition)
Contact Person: Josie Wang
Email: Send Email
Phone: +86-25 5881 2792
Address:No. 270 Jiqingmen Street, Suning Huigu, Building E6, Room 2105
City: Nanjing
Country: China
Website: https://www.nnbnutrition.com/